This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, W. W.-L. Articles by Penn, L. Z. Search for Related Content PubMed PubMed Citation Articles by Wong, W. W.-L. Articles by Penn, L. Z.

Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin¹

Department of Cellular and Molecular Biology, The Ontario Cancer Institute, University Health Network [W. W-L. W., M. M. T., Z. X., J. D., M. D. M., L. Z. P.], and Department of Medical Biophysics, University of Toronto [W. W-L. W., M. D. M., L. Z. P.], Toronto, Ontario, Canada M5G 2M9

The statin family of drugs inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, and is used clinically as a safe and effective approach in the control of hypercholesterolemia. We have shown previously (Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M D., and Penn, L. Z. Increased sensitivity of acute myelogenous leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood, 93: 1308–1318, 1999) that lovastatin, a prototypic member of the statin family, can induce apoptosis of human acute myeloid leukemia (AML) cells in a sensitive and specific manner. In the present study, we evaluated the relative potency and mechanism of action of the newer synthetic statins, fluvastatin, atorvastatin, and cerivastatin, to trigger tumor-specific apoptosis. Cerivastatin is at least 10 times more potent than the other statins at inducing apoptosis in AML cell lines. Cerivastatin-induced apoptosis is reversible with the addition of the immediate product of the HMG-CoA reductase reaction, mevalonate, or with a distal product of the pathway, geranylgeranyl pyrophosphate. This suggests protein geranylgeranylation is an essential downstream component of the mevalonate pathway for cerivastatin similar to lovastatin-induced apoptosis. The enhanced potency of cerivastatin expands the number of AML patient samples as well as the types of malignancies, which respond to statin-induced apoptosis with acute sensitivity. Cells derived from acute lymphocytic leukemia are only weakly sensitive to lovastatin cytotoxicity but show robust response to cerivastatin. Importantly, cerivastatin is not cytotoxic to nontransformed human bone marrow progenitors. These results strongly support the further testing of cerivastatin as a novel anticancer therapeutic alone and in combination with other agents in vivo.

This article has been cited by other articles:

				E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF]

				A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells Cancer Res., May 1, 2007; 67(9): 4524 - 4532. [Abstract] [Full Text] [PDF]

				V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]

				K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]

				A. H. Eliassen, G. A. Colditz, B. Rosner, W. C. Willett, and S. E. Hankinson Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer Arch Intern Med, October 24, 2005; 165(19): 2264 - 2271. [Abstract] [Full Text] [PDF]

				P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis, May 1, 2005; 26(5): 883 - 891. [Abstract] [Full Text] [PDF]

				C. Riganti, E. Miraglia, D. Viarisio, C. Costamagna, G. Pescarmona, D. Ghigo, and A. Bosia Nitric Oxide Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells by Inhibiting the Drug Efflux Cancer Res., January 15, 2005; 65(2): 516 - 525. [Abstract] [Full Text] [PDF]

				A. Horiguchi, M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8648 - 8655. [Abstract] [Full Text] [PDF]

				J. Wu, W. W.-L. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis Cancer Res., September 15, 2004; 64(18): 6461 - 6468. [Abstract] [Full Text] [PDF]

				S. Grant Reducing cholesterol and overcoming drug resistance Blood, September 15, 2004; 104(6): 1598 - 1599. [Full Text] [PDF]

				K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]